Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer-Reference-Cited by-同舟云学术

Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer

Published:2021-09-22 Issue:2 Volume:30 Page:1633-1641
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Miyawaki Taichi,Naito Tateaki^ORCID,Yabe Michitoshi,Kodama Hiroaki,Nishioka Naoya,Miyawaki Eriko,Mamesaya Nobuaki,Kobayashi Haruki,Omori Shota,Wakuda Kazushige,Ono Akira,Kenmotsu Hirotsugu,Murakami Haruyasu,Mori Keita,Harada Hideyuki,Takahashi Kazuhisa,Takahashi Toshiaki

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00520-021-06572-4.pdf

Reference35 articles.

1. Mok TSK, Wu YL, Kudaba I et al (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819–1830. https://doi.org/10.1016/S0140-6736(18)32409-7

2. Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895903. https://doi.org/10.1016/S1470-2045(17)30380-7

3. Reck M, Rodríguez-Abreu D, Robinson AG et al (2019) Updated analysis of KEYNOTE-024: Pembrolizumab versus Platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or greater. J Clin Oncol 37:537–546. https://doi.org/10.1200/JCO.18.00149

4. Rittmeyer A, Barlesi F, Waterkamp D et al (2017) Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet 389:255–265. https://doi.org/10.1016/S0140-6736(16)32517-X

5. Gandhi L, Rodríguez-Abreu D, Gadgeel S et al (2018) Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 378:2078–2092. https://doi.org/10.1056/NEJMoa1801005

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of longitudinal changes of cachexia on the efficacy and toxicity of immune checkpoint inhibitors in esophageal squamous cell cancer (ESCC) patients;Nutrition;2024-08

2. Severe weight loss during PD-1 treatment is a risk sign of poor prognosis for advanced GC patients;International Journal of Clinical Oncology;2024-07-30

3. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study;Thoracic Cancer;2024-07-29

4. Cancer cachexia as a predictor of adverse outcomes in patients with non-small cell lung cancer: A meta-analysis;Clinical Nutrition;2024-07

5. Mortality burden of pre‐treatment weight loss in patients with non‐small‐cell lung cancer: A systematic literature review and meta‐analysis;Journal of Cachexia, Sarcopenia and Muscle;2024-04-22